FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki(Enhertu) for Breast Cancer
Summary: Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive breast cancer…